local_hospital

Uniklinikum Salzburg

Address
lock Available on a paid plan

Nervous System Diseases

The department leverages advanced neuroimaging to enhance diagnosis and guide treatment of brain and spinal disorders.

  • Acute ischemic stroke with incomplete reperfusion
  • Primary generalized tonic‑clonic seizures
  • Early Parkinson’s disease
  • Primary progressive multiple sclerosis
  • Pediatric brain tumors such as medulloblastoma

Ongoing trials aim to evaluate novel therapeutic agents and device‑based interventions, seeking to improve functional recovery and long‑term neurological outcomes.

Neoplasms

Cutting‑edge imaging supports the assessment of solid and hematologic cancers across all stages.

  • Advanced breast cancer (ER+/HER2‑)
  • Non‑small cell lung cancer with molecular alterations
  • Melanoma, including high‑risk resected disease
  • Prostate cancer, localized and metastatic
  • Pediatric sarcomas such as Ewing sarcoma
  • Acute myeloid leukemia and related myelodysplastic syndromes

Studies focus on targeted therapies, immunotherapies, and combination regimens to increase survival and reduce disease recurrence.

Cardiovascular Diseases

Research integrates vascular imaging with clinical evaluation to address cardiovascular risk and heart failure.

  • Chronic heart failure with reduced ejection fraction
  • Atherosclerotic cardiovascular disease (ASCVD)
  • Elevated lipoprotein(a) levels
  • Hypertension
  • Atrial fibrillation with stroke risk

Clinical trials test new pharmacologic agents, device‑based therapies, and lifestyle interventions to lower morbidity and mortality.

Immune System Diseases

The site investigates immune‑mediated conditions, employing biomarkers to guide therapy selection for inflammatory and autoimmune disorders.

  • Crohn’s disease
  • Ulcerative colitis
  • Atopic dermatitis (moderate to severe)
  • Systemic lupus erythematosus
  • Rare skin disorders such as Netherton syndrome

Trials evaluate biologics, JAK inhibitors, and novel small molecules, aiming to achieve durable remission and improve quality of life.

Respiratory Tract Diseases

Focused investigations target chronic lung conditions, utilizing functional imaging and patient‑reported outcomes to assess respiratory health.

  • Severe eosinophilic asthma
  • Idiopathic pulmonary fibrosis
  • Chronic obstructive pulmonary disease exacerbations
  • Allergic rhinitis associated with asthma

Studies compare inhaled therapies, antifibrotic agents, and combination regimens to reduce exacerbations and preserve lung function.

Eye Diseases

Specialized imaging techniques support research on vision‑threatening ocular disorders.

  • Neovascular age‑related macular degeneration
  • Macular edema secondary to central retinal vein occlusion
  • Diabetic retinopathy requiring anti‑VEGF therapy

Clinical programs assess the efficacy of intravitreal agents, laser interventions, and extended dosing schedules to improve visual outcomes.

Site Overview

assignment
173
connected trials
corporate_fare
83
sponsors
science
255
IMPs

Activity Indicator

Last 6 months

19
Trials started
-17% vs previous period.
23
Trials started 6–12 months ago
173
Total trials linked
Highly Active
trending_downDeclining-17%
3
3
4
5
2
2
Mar
Apr
May
Jun
Jul
Aug

Trial Flow

How this site's trials are distributed across therapeutic areas and active substances (IMPs), and how they're positioned within their overall lifecycle status. Flow thickness represents the number of unique trials.

Therapeutic areaarrow_forwardIMParrow_forwardLifecycle status

Top 4 of 20 therapeutic areas and 15 of 255 IMPs, ranked by number of trials.

lock Available on a paid plan

Compounds & Molecules Timeline

The time span of clinical-trial activity for the main active substances (IMPs) studied at this site over the last 8 years. Each bar runs from the earliest trial start to the most recent end; a substance with a trial still open has no recorded end and is shown as ongoing.

Trial span Ongoing Showing last 8 years

Top 40 of 242 compounds, ranked by number of trials.

lock Available on a paid plan

Sponsor & Partnership

Top sponsors by active trials, and the ones that have come back for more than one study.

Active trials
92
Sponsors (total)
83
Active sponsors
53

Sponsor Network

Top 53 by active trials.

lock +52 more on a paid plan

Partnership History

Sponsors with repeated collaboration (≥ 2 trials).

lock +32 more on a paid plan

Sponsor Network Graph

How sponsors and therapeutic areas connect across this site's active trials: each link is at least one active trial shared between them, and bigger nodes mean more activity. Click a node to see its exact connections.

Country Benchmark

Compared to 152 other sites in Austria

description
Trial volume
173
Outperforms 97% of sites
public
Therapeutic diversity
20areas
Outperforms 98% of sites
groups
Sponsor diversity
83sponsors
Outperforms 97% of sites

Therapeutic Area Benchmark — Austria

Select a therapeutic area to compare against other sites in Austria.

Competitor Comparison

Similar sites in the same country running a comparable number of trials (within ±30%), scored on how closely their trial portfolios match this one. Higher percentages mean a more similar profile.

Country: Austria

Market Share

Country: Austria

Therapeutic Area Market Share

Select a therapeutic area to view its disease coverage breakdown.

Heat Maps & Advanced Analytics

How often specific conditions appear in trials across this site and comparable sites from the same country. Each row is a site, each column a condition, and each cell the number of trials on it — darker means more activity.

Other Trials in Uniklinikum Salzburg

lock Showing 1 of 173 trials — the rest is available on a paid plan.

Trial Sponsor Phase Status Start Date End Date
(21492 ARASTEP) A randomized, double-blind, placebo-controlled Phase 3 study of darolutamide plus androgen deprivation therapy (ADT) compared with placebo plus ADT in patients with high-risk biochemical recurrence (BCR) of prostate cancerBayer AG, Bayer Consumer Care AGPhase IIINot RecruitingOct 2023

IMP list

lock Showing 1 of 255 compounds — the rest is available on a paid plan.

IMP Trials Status First start Last start
Cyclophosphamide14Unknown2013-10-182025-10-22

Upgrade this site to Business Plan

Own the profile, publish your feasibility data and reach sponsors directly.

Is something out of date?

Tell us what needs correcting and we'll update this profile.

lock Available to Business plan sites only.